cpx-351: liposomal daunorubicin/cytarabine for aml
Published 4 years ago • 301 plays • Length 4:16Download video MP4
Download video MP3
Similar videos
-
2:14
cpx-351: liposomal daunorubicin and cytarabine for treating high-risk aml
-
2:41
lifting limits: liposomal delivery of chemotherapy for secondary aml with cpx-351
-
2:21
cpx-351 for high-risk aml
-
5:03
combining venetoclax with cpx-351 for aml
-
3:48
cpx-351 for secondary aml: pharmacokinetics, administration & impact on treatment
-
6:16
cpx-351 liposome injection vs standard cytarabine and daunorubicin for older high-risk aml patients
-
2:11
cpx-351 plus venetoclax in patients with newly-diagnosed high-risk aml
-
1:12
cpx-351 and gemtuzumab ozogamicin in r/r aml and mds
-
2:19
acute myeloid leukemia - causes, symptoms, treatments & more…
-
4:31
the impact of high and low burden tp53 mutations on risk and treatment decision in cll
-
8:11
non transplant treatments for mds & secondary aml (co-chair summary)
-
1:04
liposomal chemotherapy cpx-351: safety profile
-
3:07
improved understanding of cpx-351 in aml: impact of hct & final eap results
-
2:11
regulatory approval of cpx-351 for secondary aml
-
3:11
intensive chemotherapy: why the modern approach of cpx-351 is important for cure in aml
-
1:12
cpx-351 with venetoclax in r/r aml: results of a phase ib study
-
2:01
analyzing the cost-effectiveness of cpx-351 in patients with aml
-
3:03
cpx-351 vs. hma plus venetoclax in the treatment of patients with aml
-
0:52
a real-world study of the optimal duration of cpx-351 treatment in patients with aml
-
1:55
long-term real-world experience of cpx-351 in patients with t-aml and mrc-aml
-
1:30
evaluating the optimal duration of cpx-351 treatment & best timing for allosct consolidation in aml
-
4:13
cpx-351: liposomal cytarabine/daunorubicin in secondary aml